JOHANNESBURG - In a David vs Goliath battle, a local pharmaceutical company has won the right to continue making cancer treatment available at an affordable price for South African cancer patients.
This case has implications for the industry in relation to intellectual property law and the manufacture of generic drugs.
Lynne du Toit, CEO of Eurolab, unpacks this further